Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1

Interventions

pembrolizumab 39Gemcitabine 30Nivolumab 15Cetuximab 13Carboplatin 13Cyclophosphamide 12Cisplatin 12Irinotecan 10Docetaxel 10130-nm albumin-bound paclitaxel 10Trastuzumab 8Magnetic Resonance Spectroscopy 8fludarabine 7aldesleukin 7Paclitaxel 7Drug Therapy 7Bevacizumab 7Taxes 6Specimen Handling 6Fluorouracil 6Capecitabine 6Albumin-Bound Paclitaxel 6sargramostim 5Pemetrexed 5Oxaliplatin 5Ipilimumab 5spartalizumab 4durvalumab 4Standard of Care 4Radiotherapy 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × Automobiles × Thoracic × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡